FDA Regulatory Decisions Loom for Merck, Mirum, and Grail
Healthcare operators should track upcoming FDA decisions that could dictate market access and product commercialization strategies.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Is now a good time to invest in companies awaiting major FDA regulatory decisions?
The FDA will issue key regulatory decisions this week for three prominent healthcare firms, including Merck, Mirum, and Grail. These rulings, centered on expanding drug applications and new diagnostic approvals, will impact commercial access for products across the pharmaceutical and biotech sectors.
Why it matters
These regulatory outcomes will determine whether these companies can broaden the patient populations they serve or formalize diagnostic test availability. For operators, such decisions trigger significant shifts in competition, market coverage, and potential revenue streams for the affected product categories.
Merck reported $588 million in second-quarter sales for Winrevair, while Mirum and Grail ended June with $561.3 million and $767.6 million in cash, respectively. Mirum’s pursuit of the drug Zilurgisertib includes an upfront $16 million payment with $63 million in potential milestone costs.
The players
Merck
A multinational pharmaceutical firm with a diversified portfolio of prescription medicines, vaccines, and animal health products.
Mirum
A biopharmaceutical company focused on the development and commercialization of therapies for rare diseases.
Grail
A healthcare company specializing in multi-cancer early detection technology through blood-based diagnostic testing.
Incyte
A biopharmaceutical company focused on discovery and development of proprietary therapeutics in oncology and inflammation.
The details
The FDA is evaluating a supplemental application for Merck's Winrevair to broaden its use to patients diagnosed within the last year. Mirum is awaiting a decision on Zilurgisertib, a treatment targeting ALK2 proteins to address abnormal bone formation in FOP patients. Meanwhile, Grail's Galleri, currently a laboratory-developed test, faces an advisory committee review to determine its pathway toward formal FDA cancer screening approval.
Timeline
September 21, 2026 marks the PDUFA date for the Winrevair application.
September 23, 2026 is the scheduled advisory committee review for the Galleri test.
September 26, 2026 is the PDUFA date for the Zilurgisertib application.
Market Landscape
The regulatory timeline is governed by the Prescription Drug User Fee Act, which mandates specific review windows for drug submissions. These upcoming decisions demonstrate the application of that statutory framework to high-stakes pharmaceutical and diagnostic assets.
Operators should monitor these rulings as indicators of potential shifts in the commercial viability of pharmaceutical products and diagnostic testing protocols. Finance and strategy teams should factor these regulatory outcomes into budget projections and competitive analyses for the remainder of the year.
The takeaway
Healthcare firms should watch these FDA outcomes to gauge future market access, as they reveal the agency's current threshold for clinical evidence in high-growth niches. Track the final FDA notices for each product following these dates to update competitive strategy for the coming quarter.
Further reading
For broader trends in the sector, see Healthcare.
Live Poll
Is now a good time to invest in companies awaiting major FDA regulatory decisions?
